WS #13445
Novo Nordisk raised guidance but analysts unimpressed, with oral Wegovy and CagriSema results mixed, intensifying competition with Eli Lilly.
Novo Nordisk guidance and competition
Novo Nordisk raised guidance but analysts unimpressed, with oral Wegovy and CagriSema results mixed, intensifying competition with Eli Lilly.